Safety of Everolimus and Sirolimus‐Eluting Coronary Devices in a Patient With Porphyria Presenting With Acute Coronary Syndromes: A Two‐Year Follow‐Up

ABSTRACT We report the management of a 59‐year‐old male with genetically confirmed porphyria who underwent two percutaneous coronary interventions (PCI) using Everolimus and Sirolimus‐eluting intracoronary devices for acute coronary syndromes. The first PCI involved treatment of mid‐LAD disease with a SYNERGY Everolimus‐eluting stent. Two years later, the patient re‐presented with unstable angina and underwent further PCI using an Xience Everolimus‐eluting stent for LAD and a Sirolimus‐coated drug‐eluting balloon for a CTO in first diagonal branch. Both procedures were successful without any porphyria‐related complications. This case highlights the potential safety of Everolimus and Sirolimus‐based coronary devices in patients with porphyria.